EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

NUDT15 Pharmacogenetics in Acute Lymphoblastic Leukemia: Synthesizing Progress for Personalized Thiopurine Therapy

Isfahan Shah Lubis, Kusnandar Anggadiredja iD, Aluicia Anita Artarini, Nur Melani Sari iD, Nur Suryawan, Zulfan Zazuli iD

Medical Sciences · 05.08.2025 · 13 (3) · 112

DOI: 10.3390/medsci13030112 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Sciences, online erschienen am 05.08.2025. Verfasst von Isfahan Shah Lubis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology-Clinical Pharmacy, School of Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Pyrophosphatases, Precision Medicine, Pharmacogenetics. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bandung Institute of Technology, 2022 Research, Community Service, and Innovation (PPMI 2022) Program, School of Pharmacy, Institut Teknologi Bandung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of acute lymphoblastic leukemia (ALL), the most common pediatric malignancy, critically relies on thiopurine therapy, such as 6-mercaptopurine (6-MP), during the maintenance phase. However, significant inter-individual response variety and high risk of myelosuppression often disrupt therapy efficacy. Pharmacogenetics offer crucial strategies to personalized therapy. While thiopurine methyltransferase (TPMT) was initially the primary focus, the discovery of nudix hydrolase 15 (NUDT15) appears as a more comprehensive determinant of thiopurine intolerance. This review aims to consolidate and critically evaluate the advancement achieved in unraveling the biological mechanism and clinical significance of NUDT15 pharmacogenetics in thiopurine therapy. Foundational studies showed the vital role of NUDT15 in the detoxification of active thiopurines, with common genetic variants (for instance, p. Arg139Cys) significantly disrupting its activity, leading to the accumulation of toxic metabolites. Observational studies consistently associated NUDT15 variants with severe myelosuppression, notably in Asian populations. Recent randomized controlled trials (RCTs) confirmed that NUDT15 genotype-guided dosing effectively reduces thiopurine-induced toxicity without interfering with the therapeutic outcome. Despite these advancements, challenges remain present, including the incomplete characterization of rare variants, limited data in the diverse Asian populations, and the need for standardized integration with metabolite monitoring. In conclusion, NUDT15 pharmacogenetics is essential for improving patient safety and thiopurine dosage optimization in the treatment of ALL. For thiopurine tailored medicine to be widely and fairly implemented, future research should focus on increasing genetic data across different populations, improving the dose adjustment algorithm, and harmonizing therapeutic guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaPyrophosphatasesPrecision MedicinePharmacogeneticsMercaptopurineHumansMethyltransferasesAntimetabolites, AntineoplasticNudix Hydrolases

Stichwörter der Autor:innen

6-mercaptopurineNUDT15acute lymphoblastic leukemia (ALL)myelosuppressionpersonalized medicinepharmacogeneticsthiopurines

Substanzen

PyrophosphatasesNUDT15 protein, humanMercaptopurineMethyltransferasesthiopurine methyltransferaseAntimetabolites, AntineoplasticNudix Hydrolases

Autor:innen und Institutionen

  • Department of Pharmacology-Clinical Pharmacy, School of Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia.
  • Department of Pharmaceutics, School of Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia.
  • Division of Hematology-Oncology, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung 40161, Indonesia.

ORCID-Profile: Kusnandar Anggadiredja, Nur Melani Sari, Zulfan Zazuli

Förderung

  • Bandung Institute of Technology
  • 2022 Research, Community Service, and Innovation (PPMI 2022) Program, School of Pharmacy, Institut Teknologi Bandung

Zitieren

APA

Lubis, I. S., Anggadiredja, K., Artarini, A. A., Sari, N. M., Suryawan, N., & Zazuli, Z. (2025). NUDT15 Pharmacogenetics in Acute Lymphoblastic Leukemia: Synthesizing Progress for Personalized Thiopurine Therapy. Medical Sciences, 13(3), 112. https://doi.org/10.3390/medsci13030112

Vancouver

Lubis IS, Anggadiredja K, Artarini AA, Sari NM, Suryawan N, Zazuli Z. NUDT15 Pharmacogenetics in Acute Lymphoblastic Leukemia: Synthesizing Progress for Personalized Thiopurine Therapy. Medical Sciences. 2025;13(3):112. doi:10.3390/medsci13030112

BibTeX
@article{Lubis2025,
  author = {Lubis, Isfahan Shah and Anggadiredja, Kusnandar and Artarini, Aluicia Anita and Sari, Nur Melani and Suryawan, Nur and Zazuli, Zulfan},
  title = {NUDT15 Pharmacogenetics in Acute Lymphoblastic Leukemia: Synthesizing Progress for Personalized Thiopurine Therapy},
  journal = {Medical Sciences},
  year = {2025},
  volume = {13},
  number = {3},
  pages = {112},
  doi = {10.3390/medsci13030112}
}
Kostenlos starten →